110 related articles for article (PubMed ID: 35730395)
1. Transaminitis prevalence among HIV-infected adults eligible for tuberculosis preventive therapy.
Chaisson LH; Semitala FC; Mwebe S; Katende J; Asege L; Nakaye M; Andama AO; Atuhumuza E; Kamya M; Cattamanchi A; Yoon C
AIDS; 2022 Sep; 36(11):1591-1595. PubMed ID: 35730395
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
3. Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
Kalema N; Semeere A; Banturaki G; Kyamugabwa A; Ssozi S; Ggita J; Kabajaasi O; Kambugu A; Kigozi J; Muganzi A; Castelnuovo B; Cattamanchi A; Armstrong-Hough M
Int J Tuberc Lung Dis; 2021 May; 25(5):388-394. PubMed ID: 33977907
[No Abstract] [Full Text] [Related]
4. Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
Hahn JA; Ngabirano C; Fatch R; Emenyonu NI; Cheng DM; Adong J; Tumwegamire A; Terrault NA; Linas BP; Jacobson KR; Muyindike WR
AIDS; 2023 Aug; 37(10):1535-1543. PubMed ID: 37260251
[TBL] [Abstract][Full Text] [Related]
5. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy.
Suwanpimolkul G; Gatechompol S; Kawkitinarong K; Ueaphongsukkit T; Sophonphan J; Siriyakorn N; Jirajariyavej S; Khusuwan S; Panarat P; Wannalerdsakun S; Saetiew N; Chayangsu S; Wiwatrojanagul S; Noopetch P; Danpornprasert P; Mekviwattanawong S; Fujitnirun C; Lertpiriyasuwat C; Han WM; Kerr SJ; Ruxrungtham K; Avihingsanon A;
J Int AIDS Soc; 2022 Apr; 25(4):e25900. PubMed ID: 35384317
[TBL] [Abstract][Full Text] [Related]
6. Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda.
Nakiyingi L; Ssengooba W; Nakanjako D; Armstrong D; Holshouser M; Kirenga BJ; Shah M; Mayanja-Kizza H; Joloba ML; Ellner JJ; Dorman SE; Manabe YC
BMC Infect Dis; 2015 Feb; 15():62. PubMed ID: 25888317
[TBL] [Abstract][Full Text] [Related]
7. Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women.
Dusingize JC; Hoover DR; Shi Q; Mutimura E; Rudakemwa E; Ndacyayisenga V; Gakindi L; Mulvihill M; Sinayobye JD; Musabeyezu E; Anastos K
AIDS Res Hum Retroviruses; 2015 Jul; 31(7):723-30. PubMed ID: 25924728
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial.
Semitala FC; Chaisson LH; Dowdy DW; Armstrong DT; Opira B; Aman K; Kamya M; Phillips PPJ; Yoon C
Trials; 2022 May; 23(1):399. PubMed ID: 35550621
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of elevated liver transaminases and their relationship with alcohol use in people living with HIV on anti-retroviral therapy in Uganda.
Freiman JM; Fatch R; Cheng D; Emenyonu N; Ngabirano C; Geadas C; Adong J; Muyindike WR; Linas BP; Jacobson KR; Hahn JA
PLoS One; 2021; 16(6):e0250368. PubMed ID: 34061870
[TBL] [Abstract][Full Text] [Related]
11. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.
Hermans SM; Kiragga AN; Schaefer P; Kambugu A; Hoepelman AI; Manabe YC
PLoS One; 2010 May; 5(5):e10527. PubMed ID: 20479873
[TBL] [Abstract][Full Text] [Related]
12. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study.
Yoon C; Semitala FC; Atuhumuza E; Katende J; Mwebe S; Asege L; Armstrong DT; Andama AO; Dowdy DW; Davis JL; Huang L; Kamya M; Cattamanchi A
Lancet Infect Dis; 2017 Dec; 17(12):1285-1292. PubMed ID: 28847636
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
[TBL] [Abstract][Full Text] [Related]
14. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
[TBL] [Abstract][Full Text] [Related]
15. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV.
Chaisson LH; Saraceni V; Cohn S; Seabrook D; Cavalcante SC; Chaisson RE; Golub JE; Durovni B
AIDS; 2020 Jan; 34(1):139-147. PubMed ID: 31634189
[TBL] [Abstract][Full Text] [Related]
16. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
[TBL] [Abstract][Full Text] [Related]
17. Impact of hematocrit on point-of-care C-reactive protein-based tuberculosis screening among people living with HIV initiating antiretroviral therapy in Uganda.
Mwebe SZ; Yoon C; Asege L; Nakaye M; Katende J; Andama A; Cattamanchi A; Semitala FC
Diagn Microbiol Infect Dis; 2021 Mar; 99(3):115281. PubMed ID: 33453673
[TBL] [Abstract][Full Text] [Related]
18. The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy.
Kufa T; Chihota V; Mngomezulu V; Charalambous S; Verver S; Churchyard G; Borgdorff M
BMC Infect Dis; 2016 Jun; 16():266. PubMed ID: 27286814
[TBL] [Abstract][Full Text] [Related]
19. Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort study.
Auld AF; Kerkhoff AD; Hanifa Y; Wood R; Charalambous S; Liu Y; Agizew T; Mathoma A; Boyd R; Date A; Shiraishi RW; Bicego G; Mathebula-Modongo U; Alexander H; Serumola C; Rankgoane-Pono G; Pono P; Finlay A; Shepherd JC; Ellerbrock TV; Grant AD; Fielding K
PLoS Med; 2021 Sep; 18(9):e1003739. PubMed ID: 34491987
[TBL] [Abstract][Full Text] [Related]
20. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
